IN BRIEF: Physiomics celebrates "substantial" contract with old client
Physiomics PLC - mathematical modelling company that supports oncology drug development - Receives a "substantial" new contract by an existing "large pharma" client, though doesn't specify whom the client is. The project, which is valued at GBP178,000, involves involves pharmacokinetic-pharmacodynamic modelling in the field of DNA damage and repair fields. It is designed to help inform clinical dose and scheduling decisions. Physiomics expects this work to be completed over the course of the next six months.
Read more